ong-term antiplatelet therapy after drug-eluting stent (DES) implantation is important to prevent late stent thrombosis; [1] [2] [3] [4] however, antiplatelet therapy may be stopped because of bleeding or at the instruction of other healthcare providers who are to perform an invasive or surgical procedure on the patient. 5 This study evaluated the incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent (SES) implantation and subsequent adverse cardiac events.
From August 2004, SES implantation has been the default strategy in the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine for every percutaneous coronary intervention (PCI) in lesions with a reference diameter 2.5-3.75 mm. SES was not used if (1) primary PCI was performed in patients with acute myocardial infarction (<48 h from onset), (2) patients were likely to require an invasive or surgical procedure within the next 12 months, (3) patients were not expected to comply with long-term antiplatelet therapy, (4) difficulty in delivery was anticipated, (5) there was a risk of bleeding, (6) any contraindications to antiplatelet therapy existed, or (7) patients preferred a bare metal stent. After written informed consent was given, PCI was performed according to current standard guidelines. This study was approved by the local council on human research. All patients received aspirin (100 mg) once a day indefinitely. Ticlopidine (100 mg twice daily) or clopidogrel (50 mg daily) was given for at least 3 months. If side-effects of thienopyridine occurred, it was replaced with cilostazol.
Baseline demographic and clinical data were obtained by review of the medical records and procedural reports. A health questionnaire was sent to all patients with the following specific questions: (1) was there any occasion for discontinuation of antiplatelet agents and, (2) if yes, when and why (ie, surgery, endoscopy with or without biopsy, dental procedure, bleeding, or non-adherence), (3) were there any adverse events after the discontinuation, and (4) staged PCI or SES deployment for SES restenosis, the time between the procedure and the cessation of antiplatelet therapy was calculated from the latest SES deployment to the discontinuation. Clinical follow-up data were also obtained from outpatient record reviews. General practitioners and referring cardiologists were contacted as necessary for additional information. The occurrence of major late clinical events was recorded, including death (all-cause or cardiac), myocardial infarction, and target lesion revascularization; these were adjudicated by accompanying source documentation. Stent thrombosis was defined as (1) the presence of acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion, (2) unexplained death within 30 days after the procedure or (3) acute myocardial infarction involving the target-vessel territory without angiographic confirmation. Stent thrombosis was also classified as subacute (0-30 days) or late (>30 days). Between August 2004 and March 2007, 254 patients with 332 lesions underwent SES implantation. Multivessel stenting, including staged PCI, was performed in 60 patients. In 9 patients, another SES was deployed to treat SES restenosis. Baseline clinical, angiographic, and procedural characteristics are shown in Table 1 . Follow-up was complete for 97.2% of the population (mean 15.6±8.9 months). Premature discontinuation of antiplatelet therapy occurred for 46 patients (18.1%): twice in 8 patients and three times in 1 ( Table 2) . Mean time from SES implantation to therapy discontinuation was 10.9±6.4 months. Antiplatelet therapy was restarted in 53 (94.6%) of 56 occasions. In those patients, 1 case of late stent thrombosis (2.2%) resulting in acute myocardial infarction, occurred 10 days after the cessation of dual antiplatelet therapy because of pulmonary hemorrhage occurring 7 months after SES deployment. An unexplained death occurred 21 months after therapy discontinuation in a patient who had stopped taking the antiplatelet agents 1 month after the procedure. There were no other adverse events associated with discontinuation of antiplatelet therapy.
Late stent thrombosis after DES placement has emerged as a major concern, with the reported incidence ranging between 0.3% and 0.7%. [1] [2] [3] [4] Premature discontinuation of antiplatelet therapy markedly increases the risk of stent thrombosis, a catastrophic event that frequently leads to myocardial infarction and/or death. [1] [2] [3] [4] Antiplatelet therapy is sometimes prematurely discontinued either by the patient or by a healthcare provider. 5 The PREMIER registry 6 showed that 13.6% of patients with acute myocardial infarction who received DES stopped thienopyridine therapy within 30 days and such patients were less likely to have received discharge instructions about their medications.
Unexpected diseases may develop in patients who undergo SES implantation and the antiplatelet therapy may be stopped at the instruction of physicians, dentists, and other healthcare providers who are to perform an invasive or surgical procedure on the patient. However, some procedures (eg, minor surgery, teeth cleaning, and tooth extraction) can be performed with no or only minor risk of bleeding. 5 Surgeons may not allow patients undergoing major noncardiac surgery to take dual antiplatelet agents, but in this situation, aspirin should be continued if at all possible and the thienopyridine is restarted as soon as possible after the procedure. Park et al reported that 121 (6.3%) of 1,911 patients had >1 week interruption of antiplatelet therapy because of elective or unplanned surgical procedures, major trauma, bleeding, or noncompliance and 4 (3.3%) developed stent thrombosis. 4 As a tertiary referral center, most of our patients are referred from other institutions and after discharge from our institution, are managed by the referring physicians at peripheral centers. This may partial explain the higher incidence of discontinuation of antiplatelet therapy in the present study. Discontinuation of antiplatelet therapy in patients with SES is not infrequent. Patient education about the significant risk associated with premature cessation of antiplatelet therapy is necessitated. Patients should be specifically instructed before hospital discharge to contact their treating cardiologist before stopping any antiplatelet therapy, even if instructed to stop by another healthcare provider. Furthermore we must notify other healthcare providers of the potentially catastrophic risk of premature discontinuation of antiplatelet therapy. 
